AngioDynamics (ANGO) AI Stock Analysis

• Market Cap: $397.81M
• Dividend Yield: N/A
• Average Volume (3M): 638.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: -3.76%
• EPS Growth: 81.78%
• Country: US
• Employees: 748
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.03
• Shares Outstanding: 40,633,884
• 10 Day Avg. Volume: 357,903
• 30 Day Avg. Volume: 638,166
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 1.25
• Enterprise Value/Gross Profit: 2.48
• Enterprise Value/Ebitda: -44.47
• 1Y Price Target: $19.00
• Price Target Upside: 94.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 55 Neutral
• Price Target: $10.00 ▲(2.15% Upside)

AngioDynamics faces financial challenges with declining revenues and negative cash flows. However, strong earnings call performance, increased guidance, and strategic corporate events indicate potential for future growth. Valuation remains a concern due to negative earnings and no dividend yield.

Positive Factors

Financial Performance

AngioDynamics reported a beat on both top- and bottom-line results for FY25, indicating strong performance.

Market Potential

ANGO's stock is undervalued for the access to multiple high-growth markets it already has, along with the potential further upside from its ability to enter both DVT and coronary markets in the future.

Product Growth

Med Tech segment demonstrated significant growth, with notable increases in sales of key products like Auryon, AngioVac, and AlphaVac.

Negative Factors

Competitive Risks

Risks include lower-than-projected growth of Med Tech revenue and higher-than-expected competition.

Market Maturity

ANGO should see continued growth in Auryon, but likely more moderated comparatively over the long term given atherectomy is a mature market.

Product Concerns

Low sequential growth of the company’s AlphaVac product was noted as a concern, as more growth was expected given it is still an early product in a growing market.

AngioDynamics Business Overview & Revenue Model

Company Description

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

How the Company Makes Money

AngioDynamics makes money through the sale of its medical devices and technology solutions to hospitals, clinics, and healthcare providers. The company's revenue model is centered around manufacturing and distributing its proprietary products, which are used in the treatment of cancer and vascular diseases. Key revenue streams include sales of products like the NanoKnife System for ablative procedures, the AngioVac System for thrombus management, and its line of vascular access products. Additionally, the company forms significant partnerships with healthcare institutions and professionals to expand its market reach and enhance product adoption. AngioDynamics also invests in research and development to innovate and improve its product offerings, which helps maintain its competitive edge in the medical device industry.

AngioDynamics Financial Statement Overview

Summary

AngioDynamics faces significant financial hurdles, with declining revenues, persistent losses, and cash flow difficulties. While leverage is low, the company needs to address profitability and cash generation to improve its financial health and support future growth.

Income Statement

AngioDynamics shows a declining revenue trend over recent years, with the latest TTM revenue at $283.32M, down from $303.91M in 2024. The gross profit margin remains stable at around 53%, but the company struggles with profitability, reflected in significant negative EBIT and net income margins. The net loss has increased to $41.39M in TTM, showing a concerning trajectory.

Balance Sheet

The balance sheet displays moderate stability with a low debt-to-equity ratio of 0.03 in TTM, indicating minimal leverage. However, the equity ratio has decreased from 64% in 2023 to 65% in TTM, reflecting reduced shareholder equity. Despite a decline in total assets, the company maintains a healthy cash position.

Cash Flow

Cash flow analysis reveals challenges, as AngioDynamics reports negative operating and free cash flows. Although the free cash flow deficit has slightly reduced, the negative operating cash flow suggests cash management issues. The company's ability to convert net income to cash flow remains weak.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	292.50M	303.91M	338.75M	316.22M	291.01M
Gross Profit	147.39M	154.70M	174.25M	165.73M	156.79M
EBITDA	-8.23M	-6.13M	12.19M	11.13M	-8.90M
Net Income	-33.99M	-184.35M	-52.44M	-26.55M	-31.55M
Balance Sheet
Total Assets	280.14M	317.67M	532.64M	552.75M	561.44M
Cash, Cash Equivalents and Short-Term Investments	55.89M	76.06M	44.62M	28.82M	48.16M
Total Debt	0.00	5.91M	55.06M	32.26M	20.00M
Total Liabilities	97.17M	112.08M	154.34M	128.26M	121.98M
Stockholders Equity	182.97M	205.59M	378.30M	424.49M	439.46M
Cash Flow
Free Cash Flow	-15.27M	-33.93M	-4.27M	-11.49M	10.38M
Operating Cash Flow	-10.81M	-28.16M	78.00K	-7.19M	24.09M
Investing Cash Flow	-10.18M	123.72M	-9.75M	-19.31M	-13.71M
Financing Cash Flow	425.00K	-64.25M	25.42M	7.68M	-16.99M

AngioDynamics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Positive. The current price of 9.79 is above the 20-day moving average (MA) of 8.89, above the 50-day MA of 9.25, and above the 200-day MA of 9.48, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 65.53 is Neutral, neither overbought nor oversold. The STOCH value of 91.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANGO.

AngioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	76 Outperform	$2.21B	48.73	13.81%	0.79%	14.11%	23.98%
MMSI	74 Outperform	$5.27B	45.25	8.60%	―	10.14%	0.04%
TFX	73 Outperform	$5.62B	30.03	4.36%	1.07%	1.11%	-23.73%
STAA	56 Neutral	$1.36B	55.81	-25.55%	―	-32.59%	-667.81%
ANGO	55 Neutral	$397.81M	―	-17.50%	―	-3.76%	81.78%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
ICUI	45 Neutral	$3.11B	―	-1.78%	―	2.95%	47.92%

AngioDynamics Corporate Events

AngioDynamics Secures $25M Credit Facility with JPMorgan

On May 28, 2025, AngioDynamics, Inc. entered into a new Credit Agreement with JPMorgan Chase Bank, N.A., securing a $25 million revolving credit facility. This agreement is intended to provide financial flexibility for the company during its manufacturing transfer process, supporting its strategic growth without impacting its operations. The facility includes a maturity date of May 28, 2027, and is secured by the company’s assets, with specific financial covenants and guarantees from its subsidiary, RITA Medical Systems, LLC.

The most recent analyst rating on (ANGO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.